NASDAQ:IMRX
Immuneering Corporation Stock News
$1.53
+0.110 (+7.75%)
At Close: May 01, 2024
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
02:19am, Tuesday, 19'th Mar 2024
Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort resul
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
12:06pm, Monday, 18'th Mar 2024
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa
Immuneering Announces Participation in February Investor Conferences
08:00am, Thursday, 01'st Feb 2024
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of ca
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
04:05pm, Monday, 20'th Nov 2023
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an init
Immuneering to Present at the Morgan Stanley Healthcare Conference
08:00am, Wednesday, 06'th Sep 2023
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ini
Immuneering Corp.: Early Stage Promise, But Long-Term Investment
05:55pm, Friday, 07'th Jul 2023
IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
11:32am, Wednesday, 05'th Jul 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questio
Immuneering to Present at the Jefferies Healthcare Conference
08:00am, Tuesday, 30'th May 2023
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initi
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
08:30pm, Thursday, 04'th May 2023
Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.49 per share a year ago.
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
04:05pm, Wednesday, 12'th Apr 2023
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ini
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
05:20am, Tuesday, 11'th Apr 2023
Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - - Investor call to be held at 9:00 a.m. ET on April 18, 2023 -
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
11:26am, Monday, 27'th Mar 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questio
